The expression of p53, Ki-67 and urokinase plasminogen activator receptor in colorectal adenomas with true invasion and pseudoinvasion

APMIS

Volumn 107, Issue 7, 1999, Pages 689-694

  Hansen, Tine Plato ^a,b   Fenger, Claus ^a   Kronborg, Ole ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Adenocarcinoma in adenoma; Colorectal adenomas; Immunohistochemistry; Ki 67; p53; Pseudoinvasion; uPAR

Indexed keywords

KI 67 ANTIGEN; PLASMINOGEN ACTIVATOR; PROTEIN P53; UROKINASE;

ADENOMA; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; COLORECTAL TUMOR; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032798929     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01461.x     Document Type: Article

References (27)

1. 1. Morson BC. Precancerous conditions of the large bowel. Proc R Soc Med 1971;64:959-62.
2. 2. Fenoglio CM, Lane N. The anatomical precursor of colorectal carcinoma. Cancer 1974;34 Suppl 23.
3. 3. Gillespie PE, Chambers TJ, Chan KW, Doronzo F, Morson BC, Williams CB. Colonic adenomasa colonoscopy survey. Gut 1979;20:240-5.
4. 4. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
5. 5. Morson BC. Factors influencing the prognosis of early cancer of the rectum. Proc R Soc Med 1966;59:607-8.
6. 6. Fenoglio CM, Kaye GI, Lane N. Distribution of human colonic lymphatics in normal, hyperplastic, and adenomatous tissue. Its relationship to metastasis from small carcinomas in pedunculated adenomas, with two case reports. Gastroenterology 1973;64:51-66.
7. 7. Muto T, Bussey HJ, Morson BC. Pseudo-carcinomatous invasion in adenomatous polyps of the colon and rectum. J Clin Pathol 1973;26:25-31.
8. 8. Greene FL. Epithelial misplacement in adenomatous polyps of the colon and rectum. Cancer 1974;33:206-17.
9. 9. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
10. 10. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992;70 Suppl 6:1727-31.
11. 11. Kaklamanis L, Gatter KC, Mortensen N, Baigrie RJ, Heryet A, Lane DP, Harris AL. p53 expression in colorectal adenomas. Am J Pathol 1993;142:87-93.
12. 12. Scott N, Bell SM, Sagar P, Blair GE, Dixon MF; Quirke P. p53 expression and K-ras mutation in colorectal adenomas. Gut 1993;34:621-4.
13. 13. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-22.
14. 14. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
15. 15. Dukes CE. The classification of cancer of the rectum. J Path Bacteriol 1932;35:323-32.
16. 16. Morson BC, Sobin LH. Histological typing of intestinal tumors. In: Morson BC, Sobin LH, editors. International Histological Classification of Tumors, No. 15. Geneva: WHO, 1976.
17. 17. Nykjaer A, Kjoller L, Cohen RL, Lawrence DA, Garni-Wagner WB, Todd RF, van Zonneveld AJ, Gliemann J, Andreasen PA. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994;269:25668-76.
18. 18. Christensen L, Wiborg SA, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogenactivator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer 1996;66:441-52.
19. 19. Qizilbash AH, Meghji M, Castelli M. Pseudocarcinomatous invasion in adenomas of the colon and rectum. Dis Colon Rectum 1980;23:529-35.
20. 20. Dirschmid K, Kiesler J, Mathis G, Beller S, Stoss F, Schobel B. Epithelial misplacement after biopsy of colorectal adenomas. Am J Surg Pathol 1993;17: 1262-5.
21. 21. Pascal RR, Hertzler G, Hunter S, Goldschmid S. Pseudoinvasion with high-grade dysplasia in a colonic adenoma. Distinction from adenocarcinoma. Am J Surg Pathol 1990;14:694-7.
22. 22. Mueller J, Mueller E, Arras E, Bethke B, Stolte M, Hofler H. Stromelysin-3 expression in early (pT1) carcinomas and pseudoinvasive lesions of the colorectum. Virchows Arch 1997;430:213-9.
23. 23. Pyke C, Ralfkiaer E, Ronne E, Hoyer HG, Kirkeby L, Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994;24:131-8.
24. 24. Ohtani H, Pyke C, Danø K, Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 1995;62:691-6.
25. 25. Ganesh S, Sier CF, Heerding MM, van Krieken J, Griffioen G, Welvaart K, van de Velde VC, Verheijen JH, Lamers CB, Verspaget HW. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997;75:1793-801.
26. 26. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994;344:583-4.
27. 27. Nielsen HJ, Pappot H, Christensen IJ, Brunner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøondahl-Hansen J. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 1998;316:829-30.